1166 related articles for article (PubMed ID: 30390221)
21. Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey.
Berg AT; Dixon-Salazar T; Meskis MA; Danese SR; Le NMD; Perry MS
Epilepsy Res; 2024 Feb; 200():107280. PubMed ID: 38183688
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of six new antiseizure medications for adjunctive treatment of focal epilepsy and epileptic syndrome: A systematic review and network meta-analysis.
Tong J; Ji T; Liu T; Liu J; Chen Y; Li Z; Lu N; Li Q
Epilepsy Behav; 2024 Mar; 152():109653. PubMed ID: 38277848
[TBL] [Abstract][Full Text] [Related]
23. Adjunctive Cenobamate for Focal-Onset Seizures in Adults: A Systematic Review and Meta-Analysis.
Lattanzi S; Trinka E; Zaccara G; Striano P; Del Giovane C; Silvestrini M; Brigo F
CNS Drugs; 2020 Nov; 34(11):1105-1120. PubMed ID: 32851590
[TBL] [Abstract][Full Text] [Related]
24. Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials.
Privitera M; Bhathal H; Wong M; Cross JH; Wirrell E; Marsh ED; Mazurkiewicz-Beldzinska M; Villanueva V; Checketts D; Knappertz V; VanLandingham K
Epilepsia; 2021 May; 62(5):1130-1140. PubMed ID: 33797076
[TBL] [Abstract][Full Text] [Related]
25. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
Devinsky O; Patel AD; Cross JH; Villanueva V; Wirrell EC; Privitera M; Greenwood SM; Roberts C; Checketts D; VanLandingham KE; Zuberi SM;
N Engl J Med; 2018 May; 378(20):1888-1897. PubMed ID: 29768152
[TBL] [Abstract][Full Text] [Related]
26. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial.
Miller I; Scheffer IE; Gunning B; Sanchez-Carpintero R; Gil-Nagel A; Perry MS; Saneto RP; Checketts D; Dunayevich E; Knappertz V;
JAMA Neurol; 2020 May; 77(5):613-621. PubMed ID: 32119035
[TBL] [Abstract][Full Text] [Related]
27. Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.
Thiele E; Marsh E; Mazurkiewicz-Beldzinska M; Halford JJ; Gunning B; Devinsky O; Checketts D; Roberts C
Epilepsia; 2019 Mar; 60(3):419-428. PubMed ID: 30740695
[TBL] [Abstract][Full Text] [Related]
28. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy.
Villanueva V; García-Ron A; Smeyers P; Arias E; Soto V; García-Peñas JJ; González-Alguacil E; Sayas D; Serrano-Castro P; Garces M; Hampel K; Tomás M; Lara J; de Toledo M; Barceló I; Aledo-Serrano A; Gil-Nagel A; Iacampo L; Falip M; Saiz-Diaz RA; Gómez-Ibañez A; Sopelana D; Sanchez-Larsen A; López-González FJ
Epilepsy Behav; 2022 Dec; 137(Pt A):108958. PubMed ID: 36327646
[TBL] [Abstract][Full Text] [Related]
29. Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials.
Madan Cohen J; Checketts D; Dunayevich E; Gunning B; Hyslop A; Madhavan D; Villanueva V; Zolnowska M; Zuberi SM
Epilepsia; 2021 Sep; 62(9):2218-2227. PubMed ID: 34265088
[TBL] [Abstract][Full Text] [Related]
30. Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain.
García-Peñas JJ; Gil Nagel-Rein A; Sánchez-Carpintero R; Villanueva-Haba V
Rev Neurol; 2021 Sep; 73(S01):S1-S8. PubMed ID: 34486101
[TBL] [Abstract][Full Text] [Related]
31. Source of cannabinoids: what is available, what is used, and where does it come from?
Specchio N; Pietrafusa N; Cross HJ
Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643
[TBL] [Abstract][Full Text] [Related]
32. Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial.
Patel AD; Mazurkiewicz-Bełdzińska M; Chin RF; Gil-Nagel A; Gunning B; Halford JJ; Mitchell W; Scott Perry M; Thiele EA; Weinstock A; Dunayevich E; Checketts D; Devinsky O
Epilepsia; 2021 Sep; 62(9):2228-2239. PubMed ID: 34287833
[TBL] [Abstract][Full Text] [Related]
33. New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol.
Villanueva V; Carreño-Martínez M; Gil Nagel-Rein A; López-González FJ
Rev Neurol; 2021 Apr; 72(S01):S1-S10. PubMed ID: 33908026
[TBL] [Abstract][Full Text] [Related]
34. Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
Silvinato A; Floriano I; Bernardo WM
Rev Assoc Med Bras (1992); 2022; 68(10):1345-1357. PubMed ID: 36417631
[TBL] [Abstract][Full Text] [Related]
35. Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.
Chen JW; Borgelt LM; Blackmer AB
Ann Pharmacother; 2019 Jun; 53(6):603-611. PubMed ID: 30616356
[TBL] [Abstract][Full Text] [Related]
36. Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial.
Devinsky O; Nabbout R; Miller I; Laux L; Zolnowska M; Wright S; Roberts C
Epilepsia; 2019 Feb; 60(2):294-302. PubMed ID: 30582156
[TBL] [Abstract][Full Text] [Related]
37. Cannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea.
Koo CM; Kim SH; Lee JS; Park BJ; Lee HK; Kim HD; Kang HC
J Korean Med Sci; 2020 Dec; 35(50):e427. PubMed ID: 33372424
[TBL] [Abstract][Full Text] [Related]
38. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
Devinsky O; Cross JH; Laux L; Marsh E; Miller I; Nabbout R; Scheffer IE; Thiele EA; Wright S;
N Engl J Med; 2017 May; 376(21):2011-2020. PubMed ID: 28538134
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies.
Reddy DS
Exp Neurol; 2023 Jan; 359():114237. PubMed ID: 36206806
[TBL] [Abstract][Full Text] [Related]
40. Real-world evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or Tuberous Sclerosis Complex.
Espinosa-Jovel C; Riveros S; Bolaños-Almeida C; Salazar MR; Inga LC; Guío L
Seizure; 2023 Nov; 112():72-76. PubMed ID: 37769547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
